Attached files
| file | filename |
|---|---|
| S-1/A - FENNEC PHARMACEUTICALS INC. | v210514_s1a.htm |
| EX-5.1 - FENNEC PHARMACEUTICALS INC. | v210514_ex5-1.htm |
| EX-4.5 - FENNEC PHARMACEUTICALS INC. | v210514_ex4-5.htm |
| EX-4.6 - FENNEC PHARMACEUTICALS INC. | v210514_ex4-6.htm |
| EX-23.3 - FENNEC PHARMACEUTICALS INC. | v210514_ex23-3.htm |
EXHIBIT
23.2
|
Deloitte
& Touche LLP
|
||
|
800
– 100, Queen Street
|
||
|
Ottawa
ON K1P 5T8
|
||
|
Canada
|
||
|
Tel:
613-236-2442
|
||
|
Fax.:
613-236-2195
|
||
|
www.deloitte.ca
|
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We
consent to the use in this Amendment No.1 to Registration Statement No.
333-170570 on Form S-1 of our report dated March 30, 2010 relating to the
consolidated financial statements of Adherex Technologies Inc. (a development
stage company) (which report expresses an unqualified opinion and includes an
explanatory paragraph relating to the conditions and events that cast
substantial doubt on the Company’s ability to continue as a going concern)
appearing in the Prospectus, which is part of this Registration
Statement.
We also
consent to the reference to us under the headings "Experts" in such
Prospectus.
/s/
Deloitte & Touche LLP
Independent
Registered Chartered Accountants
Licensed
Public Accountants
Ottawa,
Canada
February
9, 2011